FDA expands approval of Regeneron's eye drug Eylea

09/23/2012 | Medscape (free registration)

Regeneron Pharmaceuticals obtained FDA approval of Eylea, or aflibercept, to treat patients with macular edema after central retinal vein occlusion. Eylea previously was approved for wet age-related macular degeneration.

View Full Article in:

Medscape (free registration)

Published in Briefs: